Literature DB >> 623943

Decreased urinary output of tyramine and its metabolites in depression.

S B Carter, M Sandler, B L Goodwin, P Sepping, P K Bridges.   

Abstract

Despite dramatic clinical improvement in about one-third of a group of severely depressed, medication-resistant patients one year after modified leucotomy, their relative decrease in conjugated and free tyramine output after an oral tyramine load remained unchanged and abnormal. Whilst a direct deficit in intestinal tyramine-conjugating ability still needs to be finally ruled out, this appears most compatible with a deficit due to bodily metabolic failure, perhaps a deficit in membrane transport which could be an essential aspect of the depressive illness syndrome. Attention is drawn to a similar defect in migraine. The two illnesses may represent a common predisposition which an appropriate triggering mechanism may transform to the florid disease. Biochemical detection of such vulnerability may have important diagnostic and predictive significance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 623943     DOI: 10.1192/bjp.132.2.125

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  3 in total

1.  High incidence of endogenous depression in migraine: confirmation by tyramine test.

Authors:  J Jarman; M Fernandez; P T Davies; V Glover; T J Steiner; C Thompson; F C Rose; M Sandler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

2.  Decreased conjugated tyramine output in depression: the effect of oral L-cysteine.

Authors:  S M Carter; B L Goodwin; M Sandler; P K Gillman; P K Bridges
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

3.  Human platelet phenolsulphotransferase M and P: substrate specificities and correlation with in vivo sulphoconjugation of paracetamol and salicylamide.

Authors:  S M Bonham Carter; G Rein; V Glover; M Sandler; J Caldwell
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.